Integra F Availability: What Providers and Prescribers Need to Know in 2026

Patients presenting with iron deficiency anemia or folate deficiency — particularly during pregnancy — are increasingly reporting difficulty filling Integra F prescriptions. While Integra F does not appear on the FDA's official drug shortage list, its niche regulatory status, single-manufacturer supply chain, and widespread insurance non-coverage create real-world availability challenges that prescribers should be prepared to address.

Understanding Integra F's Regulatory and Market Position

Integra F is marketed by U.S. Pharmaceutical Corporation as a prescription supplement containing 125 mg elemental iron (via Ferrous Fumarate and Polysaccharide Iron Complex), 1 mg folic acid, 40 mg ascorbic acid (as ProAscorb C), and 3 mg niacin. Per DailyMed labeling, this product has not been formally found by the FDA to be safe and effective, and its labeling has not been FDA-approved — placing it in the class of marketed unapproved drugs that the agency has historically tolerated in the supplement/nutrient space.

This regulatory status has significant downstream effects: the FDA shortage database does not monitor it, generic manufacturers are unlikely to enter the market, and insurance coverage is minimal. As a result, availability tracking falls entirely on prescribers and patients.

Why Pharmacies May Not Have Integra F in Stock

Several structural factors contribute to Integra F's variable pharmacy availability:

• Single-source supply chain. U.S. Pharmaceutical Corporation is the sole manufacturer. Any production disruption, raw material shortage, or distribution issue directly limits national availability with no fallback supplier.
• Limited insurance reimbursement. Most commercial payers and Medicare Part D plans exclude Integra F from formularies because similar active ingredients are available OTC. Low or absent reimbursement reduces pharmacy motivation to maintain inventory.
• Distributor gaps. Not all pharmaceutical distributors carry Integra F, meaning pharmacies served by certain wholesalers may have difficulty ordering it regardless of their own stocking preferences.
• Low prescription volume. As a niche supplement, Integra F's prescription volume is lower than mainstream iron products. Many pharmacies won't hold stock of a product that turns over slowly.

Clinical Pharmacology Recap: Why Prescribers Choose Integra F

The rationale for choosing Integra F over standard ferrous sulfate is primarily tolerability. Integra F delivers 125 mg elemental iron through two mechanisms: ferrous iron (from Ferrous Fumarate) and ferric iron complexed to a polysaccharide (Polysaccharide Iron Complex). Research cited in the prescribing information found that this combination was better tolerated and safer than Ferrous Fumarate alone, likely because distributing iron delivery across two mechanisms reduces localized GI iron load. This is a meaningful differentiator for patients who have discontinued other iron therapies due to constipation, nausea, or GI cramping.

Appropriate Alternatives When Integra F Is Unavailable

When Integra F cannot be filled, consider the following clinically reasonable alternatives, matching them to patient-specific factors:

• Integra Plus — Same dual-iron formula (125 mg elemental iron), adds comprehensive B-vitamin complex (B1, B2, B3, B5, B6, B7, B12) and higher Vitamin C (210 mg). Appropriate for patients also needing B-vitamin repletion.
• Ferralet 90 — Carbonyl iron 90 mg + folic acid 1 mg + B12 + docusate sodium. Often prescribed for obstetric patients with GI sensitivity. Lower elemental iron dose than Integra F.
• Ferrous sulfate 325 mg + folic acid 1 mg (generic) — Most cost-effective option. Approximately 65 mg elemental iron per tablet. GI side effects more common. Suitable for patients who tolerated ferrous sulfate previously.
• IV iron (Injectafer, Feraheme) — For patients who cannot tolerate oral iron or have severe deficiency, intravenous iron may be appropriate regardless of oral supplement availability.

Prescribing Guidance for Providers

To reduce patient difficulty when prescribing Integra F:

1. Include the NDC number (52747-711) on the prescription to facilitate pharmacy lookup.
2. Write prescriptions for a 90-day supply when clinically appropriate to reduce refill frequency.
3. Pre-document an acceptable alternative (e.g., Integra Plus or Ferralet 90) so patients don't need to call your office if their pharmacy is out of stock.
4. Recommend medfinder to patients. Directing patients to medfinder.com/providers enables them to efficiently locate a pharmacy with Integra F in stock without multiple pharmacy calls.
5. Consider stock at your practice. Some OB/GYN and internal medicine practices maintain a small supply of niche supplements to bridge coverage gaps for patients.

Special Considerations in Pregnancy

Integra F is specifically indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid. The prescribing information notes that before Integra F is prescribed for megaloblastic anemia in pregnancy, Addisonian pernicious anemia should be excluded, as folic acid may mask B12 deficiency signs. For obstetric patients with iron deficiency anemia, treatment gaps carry real fetal and maternal risk — ensuring a reliable refill pathway is a clinical priority.

Resources for Providers

medfinder's provider portal at medfinder.com/providers allows clinicians to help patients find medications in stock near them. Recommending this resource to patients who fill Integra F prescriptions can significantly reduce callbacks and missed treatment days.